Main content

    Pancreatic Cancer Clinical Research

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Adjuvant Therapy  |  Metastatic Pancreatic Cancer  |  Non-Metastatic Pancreatic Cancer  |  Pancreatic Neuroendocrine Tumors


    Active Trials

    Adjuvant Therapy

    Title: A Phase II-R and a Phase III Trial Evaluating Both *Erlotinib (PH II-R) and Chemoradiation (PH III) as Adjuvant Treatment For Patients With Resected Head of Pancreas Adenocarcinoma
    Description: This randomized phase II-R/III trial studies gemcitabine hydrochloride with or without erlotinib hydrochloride followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in treating patients with pancreatic cancer that was removed by surgery
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with histologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection
    Status: Please contact site for study status
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study RTOG 0848

    Back to top


    Active Trials

    Metastatic Pancreatic Cancer

    Title: A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase)Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer
    Description: PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer (HALO-109-202)
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, who have Histologically confirmed Stage IV pancreatic ductal adenocarcinoma w/ documented disseminated neoplasm to liver and /or lung. Must have archival or fresh tissue (block /slides) available pre-dose
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study HALO-109-202

    Title: A Randomized, Double-Blind, Phase 3 Study of the Janus Kinase (JAK) 1/2 Inhibitor, Ruxolitinib, or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy
    Description: This study is to determine the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of metastatic pancreatic cancer
    Investigator (CPMC): Ari Baron, MD
    Investigator (Santa Rosa): Eric Dean, MD
    Eligibility: Male subjects 18 y/o and older with histologic or cytological diagnosis of adenocarcinoma of the prostate
    Status: Active and open to enrollment
    Contact (CPMC): Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study Incyte JANUS
    Contact (Santa Rosa): Christina DeVisser, 707-576-4739, Email: DevissC@cpmcri.org about Study Incyte JANUS

    Back to top

    Active Trials

    Non-Metastatic Pancreatic Cancer

    Title: A Phase III Study of FOLFIRINOX With or Without HyperAcute®-Pancreas (Algenpantucel-L) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
    Description: Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older with a diagnosis of pancreatic cancer
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study NLG0505

    Back to top

    Active Trials

    Pancreatic Neuroendocrine Tumors

    Title: A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
    Description: This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who have histologically or pathologically confirmed locally unresectable or metastatic low or intermediate grade pancreatic neuroendocrine tumor, excluding small cell carcinoma
    Status: Please contact site for study status
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study ECOG E2211

    • updated March 2015

    Back to top